Edition:
United States

Lexicon Pharmaceuticals Inc (LXRX.OQ)

LXRX.OQ on NASDAQ Stock Exchange Global Select Market

18.63USD
23 Sep 2016
Change (% chg)

-- (--)
Prev Close
$18.63
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
260,609
52-wk High
$19.45
52-wk Low
$7.66

LXRX.OQ

Chart for LXRX.OQ

About

Lexicon Pharmaceuticals, Inc. (Lexicon) is a biopharmaceutical company. The Company focuses on the development of treatments for human disease. The Company is engaged in the development of two drug candidates: telotristat etiprate (LX1032) and sotagliflozin (LX4211). The Company's telotristat etiprate, is an orally delivered... (more)

Overall

Beta: 0.93
Market Cap(Mil.): $1,935.02
Shares Outstanding(Mil.): 103.87
Dividend: --
Yield (%): --

Financials

  LXRX.OQ Industry Sector
P/E (TTM): -- 42.52 36.60
EPS (TTM): -0.29 -- --
ROI: -5.38 -0.26 13.91
ROE: -9.59 -3.05 14.82

BRIEF-Lexicon Pharmaceuticals Q2 loss per share $0.37

* Q2 earnings per share view $-0.40 -- Thomson Reuters I/B/E/S

Aug 04 2016

BRIEF-Lexicon Pharmaceuticals announces validation by European Medicine Agency

* Lexicon announces the validation by the European Medicine Agency of the marketing authorization application for telotristat etiprate for the treatment of carcinoid syndrome

Jul 18 2016

BRIEF-Lexicon announces FDA priority review of new drug application

* FDA has granted a priority review of NDA filing and set a PDUFA target action date of November 30, 2016

May 31 2016

BRIEF-Lexicon Pharmaceuticals reports Q1 loss per share $0.34

* Lexicon Pharmaceuticals provides clinical pipeline update and reports 2016 first quarter financial results

May 03 2016

BRIEF-Lexicon says TC Houston Office Development scrapped real estate purchase and sale agreement

* Lexicon Pharmaceuticals Inc says TC Houston Office Development terminated real estate purchase and sale agreement with co

Apr 01 2016

Competitors

  Price Chg
Pfizer Inc. (PFE.N) $34.26 +0.11
Roche Holding Ltd. (ROG.S) CHF242.80 -2.70
Roche Holding Ltd. (RO.S) CHF242.80 -2.80
Merck & Co., Inc. (MRK.N) $62.96 -0.06
Bayer AG (BAYGn.DE) €90.00 -1.48
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €67.72 -0.73
Eli Lilly and Co (LLY.N) $81.16 -0.13
Abbott Laboratories (ABT.N) $42.19 -0.03
Bristol-Myers Squibb Co (BMY.N) $56.48 +0.06

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : New Constructs, LLC
$25.00
Provider : Thomson Reuters Stock Report
$25.00
Provider : ValuEngine, Inc.
$25.00
Provider : S&P Capital IQ Quantitative Report
$127.00
Provider : Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.